Predictive factors of clinical outcomes in patients with COVID-19 treated with tocilizumab: A monocentric retrospective analysis.

Giulia CassoneGiovanni DolciGiulia BesuttiLuca BragliaPaolo PavoneRomina CorsiniFabio SampaolesiValentina IottiElisabetta TeopompiMarco MassariMatteo FontanaGiulia GhidoniAnaflorina MateiStefania CrociEmanuele Alberto NegriMassimo CostantiniNicola FacciolongoCarlo Salvarani

Published in: PloS one (2022)

Evaluating a large number of clinical variables, our study did not find new predictors of outcome in COVID19 patients treated with tocilizumab. Further studies are needed to investigate the use of tocilizumab in COVID-19 and to better identify clinical phenotypes which could benefit from this treatment.

Keyphrases

rheumatoid arthritis
coronavirus disease
sars cov
juvenile idiopathic arthritis
rheumatoid arthritis patients
disease activity
respiratory syndrome coronavirus
case control